<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02600234</url>
  </required_header>
  <id_info>
    <org_study_id>1501</org_study_id>
    <nct_id>NCT02600234</nct_id>
  </id_info>
  <brief_title>REDUCE LAP-HF RANDOMIZED TRIAL I</brief_title>
  <official_title>REDUCE LAP-HF RANDOMIZED TRIAL I: A Study to Evaluate the Corvia Medical, Inc. IASD® System II to REDUCE Elevated Left Atrial Pressure in Patients With Heart Failure</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Corvia Medical</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Corvia Medical</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A study to evaluate the Corvia Medical, Inc. IASD® System II to REDUCE Elevated Left Atrial
      Pressure in Patients with Heart Failure.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The primary objective of this randomized controlled clinical study is to evaluate the
      peri-procedural safety and potential effectiveness (mechanistic effect) of implanting the
      IASD System II in heart failure patients with an LV ejection fraction &gt;40%, elevated left
      sided filling pressures, and who remain symptomatic despite optimal Guideline Directed
      Medical Therapy (GDMT). Clinical outcomes will also be evaluated.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>December 2015</start_date>
  <completion_date type="Anticipated">December 2022</completion_date>
  <primary_completion_date type="Actual">December 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Peri-procedural, and 1 month Major Adverse Cardiac, Cerebrovascular, and Renal Events (MACCRE)</measure>
    <time_frame>1 Month Post Implant</time_frame>
    <description>The primary safety outcome measure is the incidence of one or more of the following major adverse cardiac, cerebrovascular embolic, or renal events (MACCRE) defined as:
Cardiovascular death through 1-month post implant;
Embolic stroke through 1-months post implant;
Device and or procedure related adverse cardiac events through 1-month post implant;
New onset or worsening of kidney dysfunction (defined as eGFR decrease of &gt; 20 ml/min) through 1-month post implant</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in supine exercise pulmonary capillary wedge pressure (PCWP)</measure>
    <time_frame>1 Month Post Implant</time_frame>
    <description>Change in supine exercise pulmonary capillary wedge pressure (PCWP), as assessed by an independent blinded hemodynamic core laboratory, across the four values measured at each visit (values at 20W, 40W, 60W and 80W).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in exercise PEAK pulmonary capillary wedge pressure (PCWP) from baseline</measure>
    <time_frame>1 Month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiovascular death</measure>
    <time_frame>12 Months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of total (first plus recurrent) HF admissions/emergency clinic visits or acute care facilities for IV diuresis for HF</measure>
    <time_frame>12 Months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in QOL (EQ-5D)</measure>
    <time_frame>12 Months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in QOL (KCCQ score)</measure>
    <time_frame>12 Months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">44</enrollment>
  <condition>Heart Failure</condition>
  <arm_group>
    <arm_group_label>Treatment with Inter-Atrial Shunt Device</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Once all study criteria have been met, if randomized to this arm, patients will receive the IASD implant.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Once all study criteria have been met, if randomized to this arm, patients will not receive the implant. They will undergo an intracardiac echo only, with the option to crossover at 1 year.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Inter-Atrial Shunt Device</intervention_name>
    <description>An implantable device placed in the interatrial septum</description>
    <arm_group_label>Treatment with Inter-Atrial Shunt Device</arm_group_label>
    <other_name>IASD</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Intracardiac Echo</intervention_name>
    <description>Patients randomized to the control arm will undergo intra cardiac echocardiography, with examination of the atrial septum and left atrial appendage.</description>
    <arm_group_label>Control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:

          -  Chronic symptomatic Heart Failure

          -  Ongoing stable GDMT HF management and management of potential comorbidities

          -  Age ≥ 40 years old

          -  LV ejection fraction ≥ 40% within the past 3 months, without previously documented
             ejection fraction &lt;30%.

          -  Elevated left atrial pressure with a gradient compared to right atrial pressure (RAP)
             documented by end-expiratory PCWP during supine ergometer exercise ≥ 25mm Hg, and
             greater than RAP by ≥ 5 mm Hg

        Key Exclusion Criteria:

          -  MI and/or percutaneous cardiac intervention within past 3 months; CABG in past 3
             months, or current indication for coronary revascularization

          -  Cardiac Resynchronization Therapy initiated within the past 6 months

          -  Severe heart failure

          -  Inability to perform 6 minute walk test (distance &lt; 50 m), OR 6 minute walk test &gt;
             600m

          -  History of stroke, transient ischemic attack (TIA), deep vein thrombosis (DVT), or
             pulmonary emboli within the past 6 months

          -  Presence of significant valve disease

          -  Known clinically significant untreated carotid artery stenosis

          -  Currently requiring dialysis; or estimated-GFR &lt;25ml/min/1.73 m2 by CKD-Epi equation
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sanjiv Shah, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Northwestern University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Northwestern University</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cardiovascular Institute of the South</name>
      <address>
        <city>Houma</city>
        <state>Louisiana</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ochsner Clinic Foundation</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Michigan Health System</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>41809</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mt. Sinai Hospital</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wake Forest</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ohio Health</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ohio State University College of Medicine</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical University of South Carolina</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Alfred Hospital</name>
      <address>
        <city>Melbourne</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>OLVZ Aalst</name>
      <address>
        <city>Aalst</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UMC Groningen</name>
      <address>
        <city>Groningen</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Golden Jubilee Hospital</name>
      <address>
        <city>Glasgow</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Belgium</country>
    <country>Netherlands</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>France</country>
  </removed_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>November 5, 2015</study_first_submitted>
  <study_first_submitted_qc>November 6, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 9, 2015</study_first_posted>
  <last_update_submitted>July 14, 2020</last_update_submitted>
  <last_update_submitted_qc>July 14, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 16, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

